An American biotech company called Neurotrope (NASDAQ:NTRP) believes it has this proprietary platform technology with a natural compound from the depths of the ocean that they've developed called
Bryostatin.
ENPNewswire-August 14, 2019--Neurotrope Announces Publication Highlighting the Potential of
Bryostatin as a Unique Neurorestorative Therapy
The company's initial focus is on cancer, where it is capitalising on two recent scientific advances: the discovery that a complex natural product,
bryostatin, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for
bryostatin and analogs, enabling their availability for commercial development and use.
Previously, when snails were treated with
bryostatin, a single 0.5-h TS resulted in a 96-h LTM but not a 120-h LTM (Rosenegger et al., 2008; Takigami et al., 2014).
SUW133 is based on
bryostatin 1, a natural compound extracted from a marine animal called Bugula neritina.
Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-x.
The Food and Drug Administration (FDA) has recently given the approval for
Bryostatin to enter Phase II clinical trials for not only the treatment of Alzheimer's disease but also its underlying causes.
BRNI used a difficult training regimen for the mice in order to reveal that significant cognitive deficits occurred five months before plaques were detected in their brains, providing evidence that plaques and tangles are not at the root of the disease.Treatments of
Bryostatin and similar compounds synthesized at BRNI that target the enzyme PKC, which controls the creation of synapses at the molecular level, were administered for twelve weeks during the study.
This is the case of
bryostatin 1, a potent anticancer compound found in the organism Bugula neritina, a common and abundant member of the fouling community in harbors and bays.